In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genicon Sciences Corp.

Division of Thermo Fisher Scientific Inc.
www.geniconsciences.com

Latest From Genicon Sciences Corp.

Inimex Pharmaceuticals Inc.

The basis for Inimex's pipeline was born a few years ago when company founders teamed up to investigate small cationic peptides as antimicrobials for the Canadian Bacterial Diseases Network. They found that some cationic peptides didn't kill bacteria, but had the ability to prevent or treat infection in animal models. The trio led a team to concentrate on a unique expression profile that activated innate response without stimulating inflammation, and that research forms the foundation of the company's current portfolio of compounds that selectively boost immunity.
BioPharmaceutical

The Proteomic Evolution of Celera, Incyte and Myriad

Impatient with the progress of genomics, investors are looking to a new set of proteomics technologies to provide the necessary boost in research productivity. Celera, Incyte, and Myriad, the heads of which we interview in this article, have each created widely different strategies for accessing the new opportunities. Aside from differences in technology approaches, the strategies of all three firms attempt to directly address the investment world's dissatisfaction with platform models-the original business model of both Incyte and Celera. Myriad has taken a low-risk leap into the world of proteomics, spinning off its proteomics tools into a new database company that will map the proteome, delivering Myriad the information it needs for its own product discovery and development programs and selling it at the same time on a non-exclusive basis to subscribers.Celera is radically modifying its information-only strategy, transforming itself into a drug discovery company that will be assisted financially with proceeds from its database business, which will itself be boosted by new proteomic data Celera will create, review before others, and then make available to subscribers. Incyte is continuing to focus on selling information as its base business, but is adding proteomic features to its basic systems through acquisition and internal development. At the same time, it is trading access to its LifeSeq database to new proteomic technology developers for a share either of their downstream product revenues and/or rights to sell the information those products generate.
BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
      • Genomics-Proteomics
  • Pharmaceuticals
  • Research, Analytical Equipment & Supplies
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Thermo Fisher Scientific Inc.
  • Senior Management
  • Patrick Mallon, Pres. & CEO
    James Linton, PhD, VP, Bus. Dev.
    Juan Yguerabide, PhD, VP, Research
  • Contact Info
  • Genicon Sciences Corp.
    Phone: (858) 793-0276
    11585 Sorrento Valley Rd.
    San Diego, CA 92121
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register